Jobs
-
Particle manufacturing specialist Liquidia Technologies has named Benjamin Yerxa, most recently at Clearside Biomedical, as its new Chief Scientific Officer. Yerxa will oversee R&D, “including a focus on scientific collaborations,” for the company. Liquidia’s PRINT… Read more . . .
-
GlaxoSmithKline says that it will begin regulatory submissions for its umeclidinium bromide (UMEC) and vilanterol (VI) dry powder inhaler for the treatment of COPD by the end of 2012. GSK is partnered with Theravance on… Read more . . .
-
Hovione has announced the appointment of Conrad Winters as Director, Drug Product Development. Winters most recently was Senior Director of the Compound Properties Group at Xenon Pharmaceuticals and previously held positions with Merck. Hovione VP… Read more . . .
-
Alexza Pharmaceuticals has received a EU Certificate of GMP Compliance of a Manufacturer subsequent to a May 2012 inspection by the Agencia Espanola de Medicamentos y Productos Sanitarios, the company has announced. Alexza plans to… Read more . . .
-
Bend Research has announced the addition of a new stand-alone cGMP spray-drying facility for high potency drug development and manufacturing, including inhalation biotherapeutics. The company offers a range of development and particle engineering services for… Read more . . .
-
Daiichi Sankyo has announced positive Phase 3 results for its Inavir laninamivir octanoate hydrate dry powder inhaler as a prophylactic antiviral. According to the company, the study found that Inavir produced statistically significant reductions in… Read more . . .
-
A new research report titled “Global Markets for Asthma & COPD Drugs” from RnRMarketResearch.com projects that the global market for prescription asthma and COPD drugs will rise from almost $35 billion in 2011 to $38… Read more . . .
-
Florida-based Nephron Pharmaceuticals has announced that it is launching an over-the-counter racepinephrine inhalation solution delivered by a device called the EZ Breathe Atomizer. The product will be marketed as Asthmanefrin and is being promoted as… Read more . . .
-
Watson Pharmaceuticals has launched a generic levalbuterol inhalation solution, an authorized version of Sunovion’s Xopenex for the treatment of asthma. Shipments will begin immediately. The company cites IMS Health data saying that sales of Xopenex… Read more . . .
-
Astellas and AstraZeneca have announced the approval of Symbicort Turbuhaler for COPD. The budesonide/formoterol fumarate DPI has been available for the treatment of asthma in Japan since January 2010. The two companies entered an agreement… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland